J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

John­son & John­son laid out their pipeline and medtech strate­gies Tues­day, promis­ing 20 new drugs that can help grow sales 5% to 7% a year through 2030, start­ing with $57 bil­lion in 2025. R&D chief John Reed, in an ear­li­er in­ter­view with End­points News, said their three pil­lars of fo­cus would be on­col­o­gy, im­munol­o­gy and neu­ro­science.

Through­out the pre­sen­ta­tion, ex­ecs laid out the specifics of how they planned to get to their high tar­get. Here are a few of the more no­table things to come out of the af­ter­noon:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER